{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-214711","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.980501+00:00","generated_at":"2026-05-14T21:09:38.563480+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Artiva Biotherapeutics raises ~$300M in common stock and pre-funded warrant offering","bullets":["Priced 23,871,526 shares at $11.52/share and 2,170,138 pre-funded warrants at $11.5199 each.","Gross proceeds ~$300M before underwriting discounts and expenses.","Offering managed by Jefferies, TD Securities, and Cantor Fitzgerald; closing expected May 11, 2026.","Pre-funded warrants exercisable immediately with 4.99% beneficial ownership cap; cap can be increased to 19.99%.","Company registered under S-3; shares and warrants listed on Nasdaq under ARTV."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214711","json":"https://secwatch.observer/filing/0001193125-26-214711.json","markdown":"https://secwatch.observer/filing/0001193125-26-214711.md","text":"https://secwatch.observer/filing/0001193125-26-214711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526214711/0001193125-26-214711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526214711/d20969d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:09:38.563480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}